

The claims defining the invention are as follows:

1. Use of a compound of Formula I:




I ; and

a compound of Formula II:




II ; and

a compound of Formula III:



III ; and

a salt of Formula IV:



IV ;

in the manufacture of a medicament for treating HIV;

wherein the medicament is in the form of a tablet comprising a first layer and a second layer, wherein the first layer comprises the compound of Formula I and the compound of formula II, and optionally a pharmaceutically acceptable carrier, and the second layer comprises the compound of formula III and the salt of formula IV, and optionally a pharmaceutically acceptable carrier.

2. The use of claim 1, wherein the first layer of the tablet is in contact with the second layer.

3. The use of claim 1 or claim 2, wherein the weight of the compound of Formula I divided by the weight of the compound of Formula II is 1.0 ± 0.5.

4. The use of any one of claims 1 to 3, wherein the first layer of the tablet further comprises a plurality of silica particles.

5. The use of claim 4, wherein the compound of Formula II is associated with silica particles.

6. The use of any one of claims 1 to 5, wherein the tablet comprises 150 mg ± 10% of the compound of Formula I; 150 mg± 10% of the compound of Formula II;
200 mg ± 10% of the compound of Formula III; and 300 mg ± 10% of the salt of Formula IV.

7. The use of claim 6, wherein the tablet comprises 150 mg ± 5% of the compound of Formula I.

8. The use of claim 7, wherein the tablet comprises 150 mg ± 2% of the compound of Formula I.

9. The use of any one of claims 6 to 8, wherein the tablet comprises 150 mg ± 5% of the compound of Formula II.

10. The use of claim 9, wherein the tablet comprises 150 mg ± 2% of the compound of Formula II.

11. The use of any one of claims 6 to 10, wherein the tablet comprises 200 mg ± 5 % of the compound of Formula III.

12. The use of claim 11, wherein the tablet comprises 200 mg ± 2% of the compound of Formula III.

13. The use of any one of claims 6 to 12, wherein the tablet comprises 300 mg ± 5 % of the salt of Formula IV.

14. The use of claim 13, wherein the tablet comprises 300 mg ± 2% of the salt of Formula IV.

15. The use of any one of claims 1 to 14, wherein the tablet further comprises a pharmaceutically acceptable carrier.

16. The use of any one of claims 1 to 15, wherein the tablet is formulated in unit dose form.

17. The use of any one of claims 1 to 16, wherein the tablet is formulated for once a day dosing.

18. The use of claim 1, wherein the tablet core weight is 1350 mg and consists of the following components: 150.0 mg of the compound of Formula I; 150.0 mg of the compound of Formula II; 200.0 mg of the compound of Formula III; 300.0 mg of the salt of formula IV; 10.9 mg of lactose monohydrate; 267.1 mg of microcrystalline cellulose; 150.0 mg of colloidal silicon dioxide; 81.75 mg of croscarmellose sodium; 7.5 mg of hydroxypropyl cellulose; 11.25 mg of sodium lauryl sulfate; and 21.5 mg of magnesium stearate.